A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena, G A
A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. [electronic resource] - International journal of immunopathology and pharmacology - 227-33 p. digital
Publication Type: Journal Article; Multicenter Study
0394-6320
10.1177/039463200902200125 doi
Adalimumab
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Psoriasis--drug therapy
Tumor Necrosis Factor-alpha--antagonists & inhibitors
A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. [electronic resource] - International journal of immunopathology and pharmacology - 227-33 p. digital
Publication Type: Journal Article; Multicenter Study
0394-6320
10.1177/039463200902200125 doi
Adalimumab
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Psoriasis--drug therapy
Tumor Necrosis Factor-alpha--antagonists & inhibitors